南京地区无偿献血人群输血传播HBV残余风险度评估研究*

doi:10.3969/j.issn.1671-2587.2022.04.009

临床输血与检验 ›› 2022, Vol. 24 ›› Issue (4): 454-458.DOI: 10.3969/j.issn.1671-2587.2022.04.009

南京地区无偿献血人群输血传播HBV残余风险度评估研究^*

黄敏, 李燕, 张立波, 傅强

210003 南京红十字血液中心检验科

收稿日期:2021-10-22 出版日期:2022-08-20 发布日期:2022-08-19
通讯作者: 张立波,副主任技师,主要从事输血安全和采供血管理研究,（E-mail）37280240@qq.com。
作者简介:黄敏（1983-）,女,江苏南京人,副主任技师,硕士,主要从事输血安全相关问题研究,（E-mail）huangmmin@sina.com。
基金资助:
*本课题受2020年度江苏省输血协会英科新创科研基金（No.JS2020010）资助

Received:2021-10-22 Online:2022-08-20 Published:2022-08-19

摘要/Abstract

摘要： 目的对南京地区无偿献血人群HBV传播的残余风险度及不同筛查策略和模式对其的影响进行初步评估探讨。方法本文利用NAT单阳性率-窗口期比率数学模型（NAT yield/WP ratio model）,对2021年3月1日~2021年8月31日南京地区的献血人群HBV传播的残余风险度进行评估,并采用卡方检验分析比较不同的筛查策略和筛查模式对残余风险度的影响。结果 HBV血筛残余风险度卡方检验法结果：2种筛查策略[“2+1”和“1+1”]相比,χ²=1.412,P>0.05。6种筛查模式相比,χ²=7.883,P>0.05;其中[（E1+E2）+ID-NAT]和[（E1+E2）+MP-NAT]比较,χ²=0.063,P>0.05;E1+ID-NAT、E1+MP-NAT、E2+ID-NAT、E2+MP-NAT相比较,χ²=6.229,P>0.05。提示不同的筛查策略和筛查模式对HBV残余风险度的影响差异无统计学意义。结论在南京地区献血人群中,不同的血筛策略和血筛模式对HBV血筛的残余风险度在安全性上差异无统计学意义。

关键词: HBV, 残余风险, 数学模型, NAT, 筛查策略和筛查模式

中图分类号:

R457

黄敏, 李燕, 张立波, 傅强. 南京地区无偿献血人群输血传播HBV残余风险度评估研究^*[J]. 临床输血与检验, 2022, 24(4): 454-458.

参考文献

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] WANG H,MEN P X,XIAO Y F,et al.Hepatitis B infection in the general population of China:a systematic review and meta-analysis[J]. BMC Infect Dis,2019,19(1):811.
[3] LELIE N,VERMEULEN M,VAN DRIMMELEN H,et al.Direct comparison of three residual risk models for hepatitis B virus window period infections using updated input parameters[J].Vox Sang,2020,115(3):133-145.
[4] BUSCH M P,GLYNN S A,STRAMER S L,et al.A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors[J].Transfusion,2005,45(2):254-264.
[5] WEUSTEN J,VERMEULEN M,VAN DRIMMELEN H,et al.Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms[J]. Transfusion,2011,51(1):203-215.
[6] STRAMER S L,NOTARI E P,KRYSZTOF D E,et al.Hepatitis B virus testing by minipool nucleic acid testing:does it improve blood safety?[J]. Transfusion,2013,53(10 Pt 2):2449-2458.
[7] DODD R Y,CROWDER L A,HAYNES J M,et al.Screening blood donors for HIV,HCV,and HBV at the American red cross:10-year trends in prevalence,incidence,and residual risk,2007 to 2016[J]. Transfus Med Rev,2020,34(2):81-93.
[8] WHO technical report series; no.1004.WHO Expert Committee on Biological Standardization[S].Geneva: World Health Organization,2017,163-196.
[9] MIMMS L T,MOSLEY J W,HOLLINGER F B,et al.Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection[J]. BMJ,1993,307(6912):1095-1097.
[10] SABER H R,TABATABAEE S M,ABASIAN A,et al.Incidence and residual risk of HIV,HBV and HCV infections among blood donors in Tehran[J].Indian J Hematol Blood Transfus,2017,33(3):412-416.
[11] KLEINMAN S,BUSCH M P,KORELITZ J J,et al.The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection[J]. Transfus Med Rev,1997,11(3):155-172.
[12] SEED C R,CHENG A,ISMAY S L,et al.Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT[J]. Transfusion,2002,42(10):1365-1372.
[13] ZOU S M,STRAMER S L,NOTARI E P,et al.Current incidence and residual risk of hepatitis B infection among blood donors in the United States[J]. Transfusion,2009,49(8):1609-1620.
[14] SEED C R,KIELY P,KELLER A J.Residual risk of transfusion transmitted human immunodeficiency virus,hepatitis B virus,hepatitis C virus and human T lymphotrophic virus[J].Intern Med J,2005,35(10):592-598.
[15] SEED C R,KIELY P,HOAD V C,et al.Refining the risk estimate for transfusion-transmission of occult hepatitis B virus[J]. Vox Sang,2017,112(1):3-8.
[16] 余鼎,段艳,张燕,等. 两种数学模型用于重复供血浆人群丙型肝炎病毒及人类免疫缺陷病毒残余风险评估的比较[J]. 中国生物制品学杂志,2017,30(11):1220-1222.
[17] LI L,HAN T T,ZANG L,et al.The Current incidence,prevalence,and residual risk of hepatitis B viral infections among voluntary blood donors in China[J]. BMC Infect Dis,2017,17(1):754.
[18] 何子毅,陈庆恺,陈少彬,等.四种血液安全筛查模式对经血传播病毒残余风险的评估[J].中国输血杂志,2018,31(2):140-143.
[19] SHANG G F,SEED C R,WANG F,et al.Residual risk of transfusion-transmitted viral infections in Shenzhen,China,2001 through 2004[J]. Transfusion,2007,47(3):529-539.
[20] ZOU S M,FANG C T,DODD R Y.On residual risk assessment for first-time donation[J]. Transfusion,2007,47(12):2348.
[21] BUSCH M P,GLYNN S A,STRAMER S L,et al.A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors[J]. Transfusion,2005,45(2):254-264.
[22] WEN X,SU H,WANG Y,et al.Prevalence and natural course of occult hepatitis B virus infection in residents of 2 communities of Wuwei City,Gansu Province,China[J]. J Viral Hepat,2018,25(3):281-288.
[23] CORRÊA A,LAMARÃO L M,VIEIRA P C M,et al. Prevalence,incidence and residual risk of transfusion-transmitted HBV infection before and after the implementation of HBV-NAT in northern Brazil[J]. PLoS One,2018,13(12):e0208414.
[24] SCHEIBLAUER H,HEIDEN M,FUNK M,et al.Detecti on of hepatitis B virus infection in German blood donors 2008-2015[J].Vox Sang,2020,115(3):152-161.
[25] 尹湧华,孔玉洁,王美玉,等. 《血站技术操作规程(2015版)》研读[J]. 中国输血杂志,2016,29(11):1303-1305.

南京地区无偿献血人群输血传播HBV残余风险度评估研究^*

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	刘海艇, 邓智华, 蔡丹, 孟芹, 桂嵘, 王勇军, 凌锋, 王海燕, 陈军浩, 王顺, 谢华斌, 黄丽芳, 王占科, 李志波, 程金凤, 焦巍, 唐曙明, 谢小兵, 江小工, 陈亚军, 周红霞, 骆群, 黄远帅, 周明, 吕小英. 10173例检测乙型肝炎标本的血清学与核酸结果分析^*[J]. 临床输血与检验, 2020, 22(6): 583-586.
[2]	张秀红. 唐山市献血人群弓形虫抗体检测和输血残余风险分析[J]. 临床输血与检验, 2020, 22(2): 138-141.
[3]	辛菊梅. 慢性乙型肝炎及肝硬化患者HBsAg和HBV DNA定量检测的临床意义[J]. 临床输血与检验, 2020, 22(2): 203-205.
[4]	姚玮, 王久香, 霍星星, 周秋梅, 黄开泉. 乙型肝炎病毒基因分型与耐药突变基因位点的检测分析^*[J]. 临床输血与检验, 2019, 21(4): 428-430.
[5]	胡贵宾,郑艳梅,释艳华. 襄阳地区ELISA+NAT模式降低HBV输血残余风险的效果分析*[J]. 临床输血与检验, 2018, 20(3): 273-275.
[6]	张毓, 孙国栋, 张丽, 王学刚. 9例核酸反应性标本与对应ELISA、CLIA法检测HBV的关联分析[J]. 临床输血与检验, 2018, 20(2): 206-208.
[7]	谢丽鸯, 黃莉娜, 黃丽华. 龙岩地区无偿献血人群乙肝DNA阳性情况分析[J]. 临床输血与检验, 2018, 20(1): 33-35.
[8]	周怡, 史恩溢, 曹谊, 王凯, 蒋靓, 王玲玲, 陆荣. HBsAg阴性献血者隐匿性HBV感染的血清学特征及其与病毒载量的关系^*[J]. 临床输血与检验, 2017, 19(6): 570-573.
[9]	林诗雅, 王淏, 李仲平, 梁浩坚, 谢君谋, 肖韶英, 郑优荣. 2015年广州地区无偿献血者核酸和ELISA检测结果分析[J]. 临床输血与检验, 2017, 19(2): 137-141.
[10]	李莉华, 何路军, 马印图. 核酸检测系统应用于血站血液筛查的使用前确认^*[J]. 临床输血与检验, 2017, 19(2): 198-201.
[11]	程卫芳, 张浩, 周学勇, 崔伟亚, 高德玉, 张云. 核酸检测在合肥地区献血者血液筛查中的应用[J]. 临床输血与检验, 2016, 18(5): 471-474.
[12]	殷崎涛, 钱惠忠, 李玉琪, 高犁. 1例HIV低病毒载量窗口期样本的发现及对降低血液残余风险的思考[J]. 临床输血与检验, 2016, 18(4): 335-337.
[13]	李俊霞, 陈慧, 李源, 王洪, 孙国栋. 邯郸地区临床红细胞用量数学模型的建立与预测研究*[J]. 临床输血与检验, 2016, 18(3): 212-214.
[14]	林树波,肖泽斌,温国强. 汕头献血人群HBV DNA定量检测结果与乙肝两对半模式分析[J]. 临床输血与检验, 2016, 18(1): 59-61.